View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 21, 2021updated 22 Nov 2021 7:27am

Abbott reports increase in Q3 2021 sales

The global sales of Abbott's Panbio, ID NOW and BinaxNOW rapid testing platforms registered revenues of $1.6bn.

Abbott has reported sales of $10.9bn for the third quarter (Q3) of this year, representing a 23.4% increase on a reported basis as well as 22.4% on an organic basis.

On a reported basis, the company’s worldwide diagnostics sales increased by 48.2%, compared to 46.8% on an organic basis.

Global Covid-19 testing products registered revenues of $1.9bn, of which $1.6bn came from the combined global sales of Abbott’s Panbio, ID NOW and BinaxNOW rapid testing platforms.

In Core Laboratory and Molecular Diagnostics, the company’s sales for the quarter increased 5.8% and 14.9%, respectively, excluding Covid-19 testing-related sales.

Abbott’s Medical Devices business globally reported a 14.6% increase in sales. The sales increased by 18.5% on a reported basis, compared to pre-pandemic sales in 2019.

The sales of FreeStyle Libre and Libre Sense in Diabetes Care stood at $968m in the third quarter, representing a 41.6% growth on a reported basis and 38.8% on an organic basis.

Abbott president and CEO Robert Ford said: “We achieved another quarter of strong growth overall and across all four of our major business areas.

“We’re particularly pleased with the continued advancements of our new product pipeline, including several recent launches in large, high-growth markets.”

During this quarter, the company received US FDA approval for Amplatzer Amulet Left Atrial Appendage Occluder, Portico with FlexNav transcatheter aortic valve replacement (TAVR) system, and Amplatzer Talisman PFO Occlusion System.

Amplatzer Amulet Left Atrial Appendage Occluder is approved for the treatment of people with atrial fibrillation who are at risk of ischemic stroke.

The Portico with FlexNav TAVR system is used for the treatment of people with symptomatic, severe aortic stenosis.

Furthermore, the company expanded its peripheral vascular offerings with the acquisition of Walk Vascular, a commercial-stage medical device company, last month.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU